Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2011

Conditions
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
Interventions
DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Trial Locations (20)

11030

North Shore University Hospital, Manhasset

North Shore-LIJ Health System CCOP, Manhasset

14263

Roswell Park Cancer Institute, Buffalo

18105

Lehigh Valley Hospital, Allentown

19001

Abington Memorial Hospital, Abington

19958

Beebe Medical Center, Lewes

21921

Union Hospital of Cecil County, Elkton

24016

Carilion Clinic Gynecological Oncology, Roanoke

27157

Wake Forest University Health Sciences, Winston-Salem

27599

University of North Carolina, Chapel Hill

43214

Riverside Methodist Hospital, Columbus

43222

Mount Carmel Health Center West, Columbus

60612

Rush University Medical Center, Chicago

74104

Cancer Care Associates-Midtown, Tulsa

80010

Colorado Gynecologic Oncology Group, Aurora

98195

University of Washington Medical Center, Seattle

06050

The Hospital of Central Connecticut, New Britain

01655

University of Massachusetts Medical School, Worcester

02905

Women and Infants Hospital, Providence

77555-0565

University of Texas Medical Branch at Galveston, Galveston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00499252 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter